{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:52:12Z","timestamp":1787025132727,"version":"build-2736575974"},"reference-count":20,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100013528","name":"Diabetes Canada","doi-asserted-by":"publisher","award":["OG-3-21-5572-BP"],"award-info":[{"award-number":["OG-3-21-5572-BP"]}],"id":[{"id":"10.13039\/100013528","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter inhibitors (SGLTi) in type 1 diabetes increase diabetic ketoacidosis (DKA) risk but may offer kidney protection. This study assesses whether a reduced estimated glomerular filtration rate (eGFR) increases DKA risk even without SGLTi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Time-varying eGFR and hazard of first DKA event were analyzed from 35-year data in the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications study using Poisson and extended Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 1,441 participants, 297 experienced 488 DKA events. Unadjusted and adjusted DKA rates in individuals with eGFR between 30 and 90 mL\/min\/1.73 m2 showed no statistical difference compared with those with eGFR 90\u2013120 mL\/min\/1.73 m2 (incidence rate of 0.65 events per 100 person-years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>A reduced eGFR (between 30 and 90 mL\/min\/1.73 m2) alone was not associated with increased DKA risk. This finding supports further research into potential kidney-protection benefits of SGLTi for selected individuals with type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc25-1955","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:51:36Z","timestamp":1769529096000},"page":"478-482","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":1,"title":["Chronic Kidney Disease and Risk of Diabetic Ketoacidosis in Type 1 Diabetes"],"prefix":"10.2337","volume":"49","author":[{"given":"Abdulmohsen","family":"Bakhsh","sequence":"first","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Kidney & Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital & Research Centre 2 , Riyadh, Saudi Arabia"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Saleemi","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine 4 , Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Budhram","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1644-1532","authenticated-orcid":false,"given":"Yucheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto 5 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Bapat","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad I.","family":"Abuabat","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"},{"name":"Internal Medicine and Critical Care Department, King Abdullah bin Abdulaziz University Hospital, Princess Norah University 6 , Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha J.","family":"Verhoeff","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto 7 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Mumford","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Patient-partner (person with lived type 1 diabetes experience) 8 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Orszag","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fralick","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto 9 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Weisman","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto 10 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeha","family":"Cheema","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Patient-partner (person with lived type 1 diabetes experience) 8 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Rose","family":"Waniss","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto 7 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Ouimet","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto 7 , Toronto, Ontario, Canada"},{"name":"Division of Nephrology, Department of Medicine, University Health Network 11 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto 10 , Toronto, Ontario, Canada"},{"name":"Biostatistics Department, University Health Network 12 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Z.I.","family":"Cherney","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto 7 , Toronto, Ontario, Canada"},{"name":"Division of Nephrology, Department of Medicine, University Health Network 11 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Erik","family":"Lovblom","sequence":"additional","affiliation":[{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto 10 , Toronto, Ontario, Canada"},{"name":"Biostatistics Department, University Health Network 12 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-0046","authenticated-orcid":false,"given":"Bruce A.","family":"Perkins","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital 1 , Toronto, Ontario, Canada"},{"name":"Division of Endocrinology, Department of Medicine, University of Toronto 3 , Toronto, Ontario, Canada"},{"name":"Patient-partner (person with lived type 1 diabetes experience) 8 , Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto 10 , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026061811412016500_B1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2215\/CJN.02980322","article-title":"Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease","volume":"17","author":"Tuttle","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026061811412016500_B2","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-med-042921-102135","article-title":"SGLT2 inhibitors: the sweet success for kidneys","volume":"74","author":"Dharia","year":"2023","journal-title":"Annu Rev Med"},{"key":"2026061811412016500_B3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061811412016500_B4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/039139880502800307","article-title":"Serum potassium and acid-base parameters in severe dialysis-associated hyperglycemia treated with insulin therapy","volume":"28","author":"Tsamaloukas","year":"2005","journal-title":"Int J Artif Organs"},{"key":"2026061811412016500_B5","doi-asserted-by":"crossref","first-page":"dgz003","DOI":"10.1210\/clinem\/dgz003","article-title":"The long-term incidence of hospitalization for ketoacidosis in adults with established T1D-A prospective cohort study","volume":"105","author":"Thomas","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061811412016500_B6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2213-8587(23)00168-7","article-title":"People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action","volume":"11","author":"Heerspink","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061811412016500_B7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diab.35.5.530","article-title":"The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase","volume":"35","author":"The DCCT Research Group.","year":"1986","journal-title":"Diabetes"},{"key":"2026061811412016500_B8","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.2337\/dc22-1420","article-title":"Optimal frequency of urinary albumin screening in type 1 diabetes","volume":"45","author":"Perkins","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061811412016500_B9","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/dc24-2385","article-title":"Longitudinal determination of diabetes complications and other clinical variables as risk factors for diabetic ketoacidosis in type 1 diabetes","volume":"48","author":"Bapat","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061811412016500_B10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jcjd.2024.07.002","article-title":"Prognostic implications of diabetic ketoacidosis in adults on long-term mortality and diabetes-related complications","volume":"48","author":"Budhram","year":"2024","journal-title":"Can J Diabetes"},{"key":"2026061811412016500_B11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/dia.2024.0272","article-title":"Insulin pump use and diabetic ketoacidosis risk in type 1 diabetes: secular trends over four decades","volume":"27","author":"Budhram","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"2026061811412016500_B12","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"DCCT\/EDIC Research Group","year":"2011","journal-title":"N Engl J Med"},{"key":"2026061811412016500_B13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2026061811412016500_B14","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2026061811412016500_B15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00125-018-4564-8","article-title":"Regression of albuminuria and its association with incident cardiovascular outcomes and mortality in type 1 diabetes: the FinnDiane Study","volume":"61","author":"Jansson","year":"2018","journal-title":"Diabetologia"},{"key":"2026061811412016500_B16","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"2026061811412016500_B17","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2026061811412016500_B18","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026061811412016500_B19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026061811412016500_B20","doi-asserted-by":"crossref","first-page":"F667","DOI":"10.1152\/ajprenal.00400.2017","article-title":"Hyperfiltration, urinary albumin excretion, and ambulatory blood pressure in adolescents with type 1 diabetes mellitus","volume":"314","author":"Lovshin","year":"2018","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/3\/478\/855211\/dc251955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/49\/3\/478\/855211\/dc251955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:41:28Z","timestamp":1781797288000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/49\/3\/478\/164373\/Chronic-Kidney-Disease-and-Risk-of-Diabetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc25-1955","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]}}}